Comment from Heidi Cheng
AnonymousSupportIndividual
Summary: Heidi Cheng, a PharmD candidate, recommends that the FDA evaluate oral metformin as a Scenario 1 drug-repurposing candidate for treating antipsychotic-associated weight gain in adults with schizophrenia-spectrum disorders. She argues that the existing evidence base is strong and suggests that the FDA adopt transparent, criteria-based screening approaches to identify other repurposing candidates.
Please see the attached comment regarding oral metformin for antipsychotic-associated weight gain as a potential Scenario 1 drug-repurposing candidate, along with recommendations for identifying similar repurposing candidates.